Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2026)

Spyre Therapeutics (SYRE) has 3 years of Other Operating Expenses data on file, last reported at $30.0 million in Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (changed N/A YoY) and the FY2025 annual result came in at $10.0 million, changed N/A from the prior year.
• Other Operating Expenses climbed to $30.0 million in Q1 2026, from $10.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $130.5 million in Q2 2023 to a low of $1.8 million in Q4 2023.
• A 3-year average of $37.4 million and a median of $14.6 million in 2023 frame the typical range for Other Operating Expenses.